120328-90-7

Basic information

• Product Name: METHYL 2-([(E)-PHENYLMETHYLIDENE]AMINO)PROPANOATE
• Synonyms: METHYL 2-([(E)-PHENYLMETHYLIDENE]AMINO)PROPANOATE
• CAS NO: 120328-90-7
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 120328-90-7.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL 2-([(E)-PHENYLMETHYLIDENE]AMINO)PROPANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-([(E)-PHENYLMETHYLIDENE]AMINO)PROPANOATE(120328-90-7)
• EPA Substance Registry System: METHYL 2-([(E)-PHENYLMETHYLIDENE]AMINO)PROPANOATE(120328-90-7)

Safety Data

• Hazardous Substances Data: 120328-90-7(Hazardous Substances Data)

Upstream product

• 2491-20-5 L-alanine methyl ester hydrochloride 
• 100-52-7 benzaldehyde 
• 13515-97-4 methyl 2-aminopropanoate monohydrochloride 
• 73035-89-9 methyl (2R,3R)-2-amino-3-hydroxy-2-methyl-3-phenylpropanoate 
• 7625-53-8 rac-Ala-OMe 
• 10065-72-2 L-Alanine methyl ester 

Downstream Products

• 119933-91-4 3-Benzoyl-4-(4-methoxy-phenyl)-2-methyl-5-phenyl-pyrrolidine-2-carboxylic acid methyl ester 
• 111395-97-2 4-Benzoyl-3-(4-methoxy-phenyl)-2-methyl-5-phenyl-pyrrolidine-2-carboxylic acid methyl ester 
• 89902-59-0 methyl 2-methyl-c-4,7-diphenyl-6,8-dioxo-3,7-diazabicyclo-<3.3.O>octane-r-2-carboxylate 
• 28385-45-7 L-α-methylphenylalanine methyl ester 
• 38574-55-9 (R)-(-)-methyl 2-amino-2-methyl-3-phenylpropionate 
• 71785-67-6 (R)-2-Amino-2-(2-propenyl)propionsaeure-methylester 
• 88820-87-5 (S)-2-Amino-2-(2-propenyl)propionsaeure-methylester 
• 132490-23-4 1'R,2'S,5'R-menthyl r-2R-methoxycarbonyl-2-methyl-c-5R-phenylpyrrolidine-c-4S-carboxylate 
• 903890-66-4 3-[benzylideneamino]-3-methylpiperidine-2,6-dione 
• 1221507-69-2 (2S,3S,5S)-4,4-di-tert-butyl 2-methyl 3-(4-bromophenyl)-2-methyl-5-phenylpyrrolidine-2,4,4-tricarboxylate 
• 78810-45-4 (R)-2-Amino-2-methyl-5-phenyl-4-pentensaeure-methylester 
• 88825-14-3 (S)-2-Amino-2-methyl-5-phenyl-4-pentensaeure-methylester 
• 31022-10-3 N-benzyl-L-alanine methyl ester 
• 119933-95-8 3-Benzoyl-4-(4-methoxy-phenyl)-5-phenyl-pyrrolidine-2-carboxylic acid ethyl ester 

Relevant articles and documents

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

Study of 1,3-dipolar cycloaddition of amino-acid azomethines and Juglone

Novel 2,3,4,9-tetrahydro- and 4,9-dihydro-1H-benzo[f]isoindole derivatives were synthesized from Juglone and amino-acid azomethines in 74–85% yields via 1,3-dipolar cycloaddition. The stereo- and regioselectivity of cycloaddition was confirmed by NMR spec

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.